Disease on EC 1.3.98.1 - dihydroorotate dehydrogenase (fumarate)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Arthritis
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.
Arthritis, Rheumatoid
Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Dual binding mode of a novel series of DHODH inhibitors.
Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Autoimmune Diseases
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Breast Neoplasms
Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk.
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Carcinogenesis
Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation.
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Carcinoma
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis.
The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
Chagas Disease
Computational study of the mechanism of half-reactions in class 1A dihydroorotate dehydrogenase from Trypanosoma cruzi.
Cysts
Expression of the dihydroorotate dehydrogenase gene, dhod, during spermatogenesis in Drosophila melanogaster.
dihydroorotate dehydrogenase (fumarate) deficiency
Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine.
Dysostoses
Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH.
Mitochondrial nucleic acid binding proteins associated with diseases.
Foot-and-Mouth Disease
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
Hematologic Neoplasms
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Hypersensitivity
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Leishmaniasis
Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
Leishmaniasis, Cutaneous
Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Leukemia
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Leukemia, Myeloid, Acute
Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia.
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Lymphoma
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Malaria
A high-throughput fluorescence-based assay for Plasmodium dihydroorotate dehydrogenase inhibitor screening.
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.
Measles
Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
Melanoma
Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine.
DHODH modulates transcriptional elongation in the neural crest and melanoma.
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma.
Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.
The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.
Metabolism, Inborn Errors
Choline-related-inherited metabolic diseases-A mini review.
Mouth Diseases
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
Multiple Myeloma
Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Multiple Sclerosis
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Neoplasms
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition.
Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition.
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
Neuroblastoma
Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo.
Oral Ulcer
Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?
Parasitic Diseases
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
Psoriasis
Evaluation of WO2013076170: the use of a dihydroorotate dehydrogenase inhibitor for the treatment of psoriasis.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Schistosomiasis
Structural basis for the design of selective inhibitors for Schistosoma mansoni dihydroorotate dehydrogenase.
Vesicular Stomatitis
Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.
Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export.
Virus Diseases
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.